Schizophrenia Spectrum Clinical Trial
Official title:
Target Engagement for Oxytocin: Response to 8 Doses
This study will evaluate the effect of 8 doses of intranasal oxytocin or placebo on two proposed measures of target engagement in brain. The targets are (1) the suppression of a particular wave form (mu) on the electroencephalogram (EEG) while subjects observe a socially relevant form of motion and (2) pupil dilation will subjects identify faces showing different emotions.
Subjects with schizophrenia spectrum disorders will be randomly assigned to one of 8 doses of oxytocin. After screening and informed consent subjects will receive either their assigned dose or a placebo. Thirty minutes following the drug administration patients will be evaluated on the EEG and pupillometry tasks followed by two tests that evaluate social salience. One week later subjects will have a second challenge in the alternative (drug or placebo) condition. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04922593 -
Relative Bioavailability of LY03010 Compared to Listed Drug
|
Phase 1 |